Neuberger Berman Group LLC Acquires Shares of 5,446 Repligen Corporation (NASDAQ:RGEN)

Key Points

• Neuberger Berman Group LLC has acquired 5,446 shares of Repligen Corporation, valued at approximately $693,000, in its first quarter investment.
• Multiple large investors, such as KBC Group NV and GAMMA Investing LLC, have increased their stakes in Repligen, bringing institutional ownership to 97.64% of the company's stock.
• Analysts have mixed ratings on Repligen, with the average price target set at $169.45 and several institutions assigning "buy" and "hold" ratings, indicating a prevailing optimism about the stock despite earnings misses.

Neuberger Berman Group LLC acquired a new stake in Repligen Corporation (NASDAQ:RGEN - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 5,446 shares of the biotechnology company's stock, valued at approximately $693,000.

Other large investors have also modified their holdings of the company. KBC Group NV lifted its position in shares of Repligen by 14.9% during the first quarter. KBC Group NV now owns 2,544 shares of the biotechnology company's stock worth $324,000 after purchasing an additional 329 shares during the last quarter. Harvest Fund Management Co. Ltd bought a new position in shares of Repligen during the first quarter worth about $132,000. GAMMA Investing LLC lifted its position in shares of Repligen by 40.1% during the first quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company's stock worth $122,000 after purchasing an additional 274 shares during the last quarter. XTX Topco Ltd lifted its position in shares of Repligen by 34.2% during the first quarter. XTX Topco Ltd now owns 12,935 shares of the biotechnology company's stock worth $1,646,000 after purchasing an additional 3,295 shares during the last quarter. Finally, TD Asset Management Inc lifted its position in shares of Repligen by 10.9% during the first quarter. TD Asset Management Inc now owns 51,172 shares of the biotechnology company's stock worth $6,511,000 after purchasing an additional 5,014 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently commented on RGEN. Barclays began coverage on shares of Repligen in a research report on Tuesday, June 24th. They set an "overweight" rating and a $150.00 price target on the stock. HC Wainwright reiterated a "buy" rating and set a $180.00 price objective on shares of Repligen in a research note on Monday, May 5th. Evercore ISI dropped their price objective on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 8th. JPMorgan Chase & Co. dropped their price objective on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. Finally, Wall Street Zen lowered shares of Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, Repligen currently has a consensus rating of "Moderate Buy" and an average price target of $169.45.

Repligen Stock Performance

RGEN opened at $124.35 on Friday. The business's 50 day moving average is $122.50 and its 200-day moving average is $132.99. The stock has a market cap of $7.00 billion, a PE ratio of -497.38, a price-to-earnings-growth ratio of 2.33 and a beta of 1.05. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. Repligen Corporation has a twelve month low of $102.96 and a twelve month high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). The business had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The business's quarterly revenue was up 14.8% on a year-over-year basis. During the same period last year, the firm posted $0.40 EPS. On average, analysts predict that Repligen Corporation will post 1.72 earnings per share for the current year.

Insider Buying and Selling at Repligen

In other Repligen news, Director Martin D. Madaus purchased 1,800 shares of the business's stock in a transaction dated Friday, August 8th. The shares were bought at an average price of $112.13 per share, with a total value of $201,834.00. Following the completion of the acquisition, the director owned 1,800 shares in the company, valued at approximately $201,834. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.20% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.